Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness [Internet]

Kellee Kaulback; Andrea Ryce

Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness [Internet]

Review

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Mar 17.

CADTH Rapid Response Reports.

Authors

Kellee Kaulback, Andrea Ryce

PMID: 29293300
Bookshelf ID: NBK470734

Excerpt

The objective of this Rapid Response report is to evaluate the clinical and cost-effectiveness of TDF plus FTC, with or without integrase strand transfer inhibitors, as compared with other NRTI regimens with or without protease inhibitors boosted with ritonavir.

Sections

Context and Policy Issues
Research Question
Key Findings
Methods
Summary of Evidence
Conclusions and Implications for Decision or Policy Making
References
Appendix 1. Selection of Included Studies
Appendix 2. Characteristics of Included Studies
Appendix 3. Critical Appraisal of Included Publications
Appendix 4. Main Study Findings and Author’s Conclusions
Appendix 5. Additional References of Potential Interest

Publication types

Review